Calcium Pyrophosphate Deposition Disease, Rheumatic Diseases
Conditions
Keywords
Calcium pyrophosphate deposition disease, gene expression, acute clinical phenotype, chronic clinical phenotype, metabolic expression
Brief summary
The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD. The hypotheses are as follows : * It is hypothesised that there is a transcriptomic and metabolomic signature of CPPD which explains why therapeutic responses to different anti-inflammatory treatments differ from one phenotype to another one * It is hypothesised that the acute and chronic clinical phenotypes of CPPD have different clinical, biological and imaging characteristics, as well as a differing predisposition toward crystalline deposition and inflammatory pathway activation. The management of participants with chronic forms of the disease included in this research was modelled on the usual recommended management, including a biological workup, joint puncture, ultrasound and radiographic workup. Double-energy CT scans and transcriptomic and metabolomic analyses on plasma are not routine tests.
Interventions
GENETICtranscriptomic and metabolomic analysis
Venous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C.
Sponsors
Lille Catholic University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
The PYC-OMIC study is a prospective, single-centre, cross-sectional, comparative study of chronic versus acute forms of CPPD. It is an interventional study with minimal risks and constraints for chronic forms recruited prospectively. Acute forms are included retrospectively.
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- Acute forms of CPPD: retrospective part of the study * Cases included in the COLCHICORT cohort (NCT03128905), for whom this was the first acute episode of CPPD Inclusion Criteria - Chronical forms of CPPD : prospective part of the study * Patients affiliated to the French social security system * Age ≥ 65 years * Diagnosis of chronic CPPD (recurrent acute or persistent arthritis), meeting ACR/EULAR 2023,11 classification criteria after evaluation by a rheumatologist in the rheumatology department * Progression of CPPD rheumatism for at least 3 months and still active CPPD rheumatism, defined by a visual analogue scale (VAS) of disease activity ≥ 40 and/or presentation of at least 1 crisis over the last 3 months * Glomerular Filtration Rate (GFR) in Chronic Kidney Disease Epidemiology (CKD EPI Collaboration) ≥ 30ml/min/1.73m2 * Minimum time between the last intake of a crisis treatment and inclusion in the study, depending on their half-life, in order to not interfere with the results of the omics analyses: 2 weeks (Nonsteroidal Anti-Inflammatory Drugs Per Os (PO) or Intramuscular (IM) or Intravenous (IV); corticosteroids PO or IV; colchicine PO; anakinra Subcutaneous (SC), 1 month (methotrexate PO, tocilizumab SC), 3 months (canakinumab SC, tocilizumab IV) * Signed written consent for study participation
Exclusion criteria
- Acute forms of CPPD: * Missing data concerning transcriptomic and metabolomic analyses. * Opposition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptomic profile | 2 weeks | -Quantitative transcriptomic profiling (expression of the genes involved) and qualitative profiling (analysis of the sequence of variants expressed) |
| Metabolomic profile | 2 weeks | \- Metabolomic profile: quantitative assessment of the metabolites involved in each phenotype, then qualitatively grouped by activated metabolic pathway |
Countries
France
Contacts
Primary ContactMarie Paule LEBITASY
Backup ContactMarie DESOLERE
Outcome results
None listed